TA133 Asthma (uncontrolled) - omalizumab: review decision - November 2010
Review of NICE Technology Appraisal Guidance No. 133; Omalizumab for severe persistent allergic asthma
The Institute was proposing that a review of the existing guidance should be should be combined with the review of the guidance of the related ongoing technology appraisal ‘Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11’ (since published in October 2010 as TA no.201) and planned into the appraisal work programme.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. It is accepted that the amount of new evidence available to inform this review is relatively limited; however, a combined review has been explicitly recommended by the Appraisal Committee following the development of TA201, to ensure that there is no inequality in guidance for adult and paediatric populations.
After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided that a review of the original guidance should be planned into the NICE work programme.
This page was last updated: 23 December 2010